CHICAGO – Bristol-Myers Squibb Co.'s programmed cell death-1 inhibitor Opdivo (nivolumab), cleared by the FDA late last year for melanoma and in March for squamous non-small-cell lung cancer (NSCLC), worked better than the firm's other approved melanoma drug Yervoy (ipilimumab) in patients with previously untreated cases of the deadly skin cancer not only when the two drugs were given together but also when Opdivo was administered by itself.